Jefferies Financial Group Portfolio holdings
Jefferies Financial Group is the investment banking and capital markets company that was known as Leucadia National until 2018, when it took the name of the bank it merged with in 2013. Leucadia traces back to Ian Cumming and Joseph Steinberg, Harvard Business School graduates who started out at the investment bank Carl Marks & Company and in 1979 took control of Talcott National, renaming it Leucadia the next year. As a holding company it bought and resold businesses, such as the insurer Colonial Penn, acquired in 1991 and sold in two pieces in 1997, and the telecoms company WilTel, acquired in 2003 and sold in 2005. Jefferies itself grew from a small equities trading shop into a full-service investment bank, and Richard Handler became chief executive of the combined company in 2013.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$204M |
| 2 |
SPDR Gold Trust
GLD
|
+$94.6M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$88.3M |
| 4 |
Intel
INTC
|
+$58.2M |
| 5 |
Boeing
BA
|
+$54.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$640M |
| 2 |
Apple
AAPL
|
+$234M |
| 3 |
Meta Platforms (Facebook)
META
|
+$128M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$114M |
| 5 |
PTC Therapeutics
PTCT
|
+$111M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 59.53% |
| 2 | Healthcare | 11.13% |
| 3 | Technology | 8.29% |
| 4 | Industrials | 4.73% |
| 5 | Financials | 4.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Ethos Technologies Inc
LIFE
$2.18B
| $26.2M | 0.19% |
+779,999
| New | +$23.3M |
2026 Q3
0 quarters
|
|
102
Bristol-Myers Squibb
BMY
$127B
| $26.1M | 0.19% |
418,780
-89,960
| -18% | -$5.69M |
2022 Q4
15 quarters
|
|
|
103
CALL
Meta Platforms (Facebook)
META
$1.56T
| $26M | 0.19% |
35,800
-14,700
| -29% | -$9.18M |
2026 Q2
1 quarter
|
|
104
Edwards Lifesciences
EW
$58.7B
| $25.6M | 0.19% |
296,800
+257,180
| +649% | +$22.9M |
2025 Q3
4 quarters
|
|
105
Boston Scientific
BSX
$62B
| $25.4M | 0.19% |
581,801
+580,905
| +64,833% | +$26.9M |
2022 Q4
15 quarters
|
|
106
PUT
State Street SPDR Bloomberg Convertible Securities ETF
CWB
$5.12B
| $25.3M | 0.19% |
250,000
+50,000
| +25% | +$5.15M |
2026 Q2
1 quarter
|
|
|
ETRA
107
Electra Therapeutics, Inc. Common stock
ETRA
$490M
| $25.2M | 0.19% |
+2,244,333
| New | +$27.6M |
2026 Q3
0 quarters
|
|
108
Lowe's Companies
LOW
$126B
| $25.1M | 0.19% |
135,961
+85,811
| +171% | +$17.8M |
2025 Q1
6 quarters
|
|
109
EOG Resources
EOG
$76.3B
| $24.7M | 0.18% |
+179,000
| New | +$25.5M |
2026 Q3
0 quarters
|
|
110
Abbott
ABT
$190B
| $24.6M | 0.18% |
248,989
+238,216
| +2,211% | +$24.9M |
2022 Q4
15 quarters
|
|
111
GE HealthCare
GEHC
$37.2B
| $24.3M | 0.18% |
371,013
+133,360
| +56% | +$9.02M |
2023 Q1
14 quarters
|
|
112
CALL
State Street Financial Select Sector SPDR ETF
XLF
$54.2B
| $23.4M | 0.17% |
437,500
+287,500
| +192% | +$16.3M |
2025 Q2
5 quarters
|
|
|
113
CALL
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$18B
| $23.2M | 0.17% |
300,000
+245,000
| +445% | +$19.4M |
2026 Q2
1 quarter
|
|
114
Vestis
VSTS
$1.88B
| $23.1M | 0.17% |
1,731,475
+550,000
| +47% | +$7.67M |
2025 Q4
3 quarters
|
|
115
Accenture
ACN
$154B
| $23.1M | 0.17% |
126,100
+91,186
| +261% | +$15.4M |
2024 Q2
9 quarters
|
|
116
Castle Biosciences
CSTL
$1B
| $23M | 0.17% |
647,391
| – | – |
2026 Q2
1 quarter
|
|
117
PUT
TSMC
TSM
$1.95T
| $22.8M | 0.17% |
50,000
+15,000
| +43% | +$6.36M |
2026 Q2
1 quarter
|
|
118
Pfizer
PFE
$168B
| $22.6M | 0.17% |
792,649
+150,526
| +23% | +$4M |
2022 Q4
15 quarters
|
|
119
IQVIA
IQV
$44.8B
| $21.7M | 0.16% |
80,735
-4,167
| -5% | -$1.01M |
2024 Q1
10 quarters
|
|
120
Strategy Inc
MSTR
$54.6B
| $21.6M | 0.16% |
140,848
-1,685
| -1% | -$195K |
2024 Q4
7 quarters
|
|
121
UnitedHealth
UNH
$353B
| $21.5M | 0.16% |
58,579
-69,166
| -54% | -$27.8M |
2022 Q4
15 quarters
|
|
122
Becton Dickinson
BDX
$57.7B
| $21.1M | 0.16% |
118,000
+105,550
| +848% | +$18.3M |
2025 Q4
3 quarters
|
|
123
Ultragenyx Pharmaceutical
RARE
$1.57B
| $20.1M | 0.15% |
1,339,814
+410,188
| +44% | +$9.8M |
2025 Q4
3 quarters
|
|
124
Home Depot
HD
$343B
| $20M | 0.15% |
70,348
+49,994
| +246% | +$16.4M |
2022 Q4
15 quarters
|
|
|
125
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$780B
| $19.1M | 0.14% |
25,000
-45,000
| -64% | -$34.2M |
2025 Q4
3 quarters
|
|
Similar funds
Jefferies Financial Group's Q3 2026 Portfolio in Review
As of Q3 2026, Jefferies Financial Group held 1,968 positions worth $13.5B, down 11% from $15.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Jefferies Financial Group withdrew a net $3.53B in Q3 2026, closing 703 positions and reducing 401 holdings. Its most notable exit was PTC Therapeutics, an estimated $111M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 60% of assets, up from 50% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Jefferies Financial Group opened a new position in Emcor worth $40.1M.
- Jefferies Financial Group's largest Q3 2026 buy was Emcor: 53,175 shares worth $40.1M.
- Jefferies Financial Group added most to iShares iBoxx $ High Yield Corporate Bond ETF in Q3 2026, an estimated $204M increase.
- Jefferies Financial Group's biggest Q3 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $640M.
- Jefferies Financial Group fully exited PTC Therapeutics in Q3 2026, selling an estimated $111M.
- Jefferies Financial Group's ten largest holdings make up 34% of its $13.5B portfolio in Q3 2026.
- Jefferies Financial Group opened 337 new positions and closed 703 in Q3 2026.
- Jefferies Financial Group's portfolio value fell 11% quarter-over-quarter to $13.5B.
Based on Jefferies Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.